| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Effects of intensive glucose lowering in type 2 diabetes.
|
N Engl J Med
|
2008
|
47.90
|
|
2
|
Effects of intensive blood-pressure control in type 2 diabetes mellitus.
|
N Engl J Med
|
2010
|
21.49
|
|
3
|
Effects of combination lipid therapy in type 2 diabetes mellitus.
|
N Engl J Med
|
2010
|
16.40
|
|
4
|
A randomized trial of therapies for type 2 diabetes and coronary artery disease.
|
N Engl J Med
|
2009
|
12.15
|
|
5
|
Effects of medical therapies on retinopathy progression in type 2 diabetes.
|
N Engl J Med
|
2010
|
10.75
|
|
6
|
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods.
|
Am J Cardiol
|
2007
|
9.62
|
|
7
|
Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.
|
Lancet
|
2010
|
9.20
|
|
8
|
Long-term effects of intensive glucose lowering on cardiovascular outcomes.
|
N Engl J Med
|
2011
|
8.14
|
|
9
|
The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study.
|
BMJ
|
2010
|
6.11
|
|
10
|
Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
|
Am J Cardiol
|
2007
|
4.78
|
|
11
|
Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
|
Am J Cardiol
|
2007
|
4.21
|
|
12
|
Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
|
Am J Cardiol
|
2007
|
4.14
|
|
13
|
Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial.
|
Diabetes Care
|
2010
|
4.10
|
|
14
|
Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial.
|
Lancet
|
2014
|
3.53
|
|
15
|
Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
|
Am J Cardiol
|
2007
|
3.49
|
|
16
|
The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study.
|
BMJ
|
2010
|
3.26
|
|
17
|
Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
|
Am J Cardiol
|
2007
|
3.10
|
|
18
|
Recruitment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
|
Am J Cardiol
|
2007
|
2.98
|
|
19
|
Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
|
Diabetes Care
|
2010
|
2.42
|
|
20
|
Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
|
Am Heart J
|
2008
|
2.40
|
|
21
|
Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial.
|
JAMA Intern Med
|
2014
|
2.25
|
|
22
|
Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial.
|
Diabetes Care
|
2014
|
2.20
|
|
23
|
Intensive blood pressure control, falls, and fractures in patients with type 2 diabetes: the ACCORD trial.
|
J Gen Intern Med
|
2014
|
2.20
|
|
24
|
Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
|
Diabetes Care
|
2010
|
2.15
|
|
25
|
Dyslipidemia and cardiovascular risk: the importance of early prevention.
|
QJM
|
2009
|
2.14
|
|
26
|
The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD trial.
|
Diabetes Care
|
2015
|
1.93
|
|
27
|
The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study.
|
Ophthalmology
|
2014
|
1.89
|
|
28
|
The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods.
|
Am J Cardiol
|
2007
|
1.85
|
|
29
|
Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial.
|
Diabetes Care
|
2013
|
1.71
|
|
30
|
The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study.
|
Diabetes Care
|
2011
|
1.66
|
|
31
|
Intensive blood pressure treatment does not improve cardiovascular outcomes in centrally obese hypertensive individuals with diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial.
|
Diabetes Care
|
2012
|
1.55
|
|
32
|
Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial.
|
Diabetes Care
|
2012
|
1.51
|
|
33
|
Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Diabetes Mellitus: Action to Control Cardiovascular Risk in Diabetes Blood Pressure Trial.
|
Hypertension
|
2015
|
1.49
|
|
34
|
Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD-EYE).
|
Am J Cardiol
|
2007
|
1.47
|
|
35
|
Durable change in glycaemic control following intensive management of type 2 diabetes in the ACCORD clinical trial.
|
Diabetologia
|
2014
|
1.42
|
|
36
|
Biomarkers related to severe hypoglycaemia and lack of good glycaemic control in ACCORD.
|
Diabetologia
|
2015
|
1.41
|
|
37
|
Depression predicts all-cause mortality: epidemiological evaluation from the ACCORD HRQL substudy.
|
Diabetes Care
|
2012
|
1.37
|
|
38
|
Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants.
|
Diabetes Care
|
2012
|
1.14
|
|
39
|
Clinical implications of the ACCORD trial.
|
J Clin Endocrinol Metab
|
2011
|
1.05
|
|
40
|
Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus.
|
Diabetes Metab Syndr Obes
|
2014
|
1.05
|
|
41
|
Severe hypoglycemia symptoms, antecedent behaviors, immediate consequences and association with glycemia medication usage: Secondary analysis of the ACCORD clinical trial data.
|
BMC Endocr Disord
|
2012
|
1.03
|
|
42
|
Effect of intensive glycemic lowering on health-related quality of life in type 2 diabetes: ACCORD trial.
|
Diabetes Care
|
2011
|
1.00
|
|
43
|
Buffy coat specimens remain viable as a DNA source for highly multiplexed genome-wide genetic tests after long term storage.
|
J Transl Med
|
2011
|
1.00
|
|
44
|
Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study.
|
Diabetes Care
|
2016
|
1.00
|
|
45
|
Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes.
|
Kidney Int
|
2014
|
0.99
|
|
46
|
Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes.
|
Diabetes Care
|
2016
|
0.95
|
|
47
|
Health-related quality of life and cost-effectiveness components of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: rationale and design.
|
Am J Cardiol
|
2007
|
0.94
|
|
48
|
Diabetic retinopathy, its progression, and incident cardiovascular events in the ACCORD trial.
|
Diabetes Care
|
2012
|
0.91
|
|
49
|
Insulin Dose and Cardiovascular Mortality in the ACCORD Trial.
|
Diabetes Care
|
2015
|
0.89
|
|
50
|
Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies.
|
Vasc Health Risk Manag
|
2009
|
0.88
|
|
51
|
Determinants of weight gain in the action to control cardiovascular risk in diabetes trial.
|
Diabetes Care
|
2013
|
0.87
|
|
52
|
Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study).
|
Am J Cardiol
|
2014
|
0.84
|
|
53
|
Baseline comparison of three health utility measures and the feeling thermometer among participants in the Action to Control Cardiovascular Risk in Diabetes trial.
|
Cardiovasc Diabetol
|
2012
|
0.84
|
|
54
|
IDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin Therapy.
|
Diabetes Ther
|
2015
|
0.83
|
|
55
|
Genetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control in Type 2 Diabetes: Findings From the ACCORD Clinical Trial.
|
Diabetes Care
|
2016
|
0.82
|
|
56
|
Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial.
|
Diabetes Care
|
2012
|
0.81
|
|
57
|
Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial.
|
Diabetes Care
|
2013
|
0.80
|
|
58
|
Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience.
|
Diabetologia
|
2012
|
0.80
|
|
59
|
Direct cardiovascular effects of glucagon like peptide-1.
|
Diabetol Metab Syndr
|
2013
|
0.80
|
|
60
|
A genome-wide study of lipid response to fenofibrate in Caucasians: a combined analysis of the GOLDN and ACCORD studies.
|
Pharmacogenet Genomics
|
2016
|
0.79
|
|
61
|
The cross-sectional and longitudinal associations of diabetic retinopathy with cognitive function and brain MRI findings: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
|
Diabetes Care
|
2014
|
0.79
|
|
62
|
Systolic Blood Pressure Control Among Individuals With Type 2 Diabetes: A Comparative Effectiveness Analysis of Three Interventions.
|
Am J Hypertens
|
2015
|
0.78
|
|
63
|
Efficacy and Safety of Vildagliptin as an Add-on to Insulin with or without Metformin in Japanese Patients with Type 2 Diabetes Mellitus: A 12-week, Double-Blind, Randomized Study.
|
Diabetes Ther
|
2015
|
0.78
|
|
64
|
The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers.
|
Diabetes Res Clin Pract
|
2011
|
0.78
|
|
65
|
Cardiovascular Outcome Studies in Diabetes: How Do We Make Sense of These New Data?
|
Diabetes Ther
|
2016
|
0.77
|
|
66
|
Dipeptidyl peptidase-4 inhibitors improve arterial stiffness, blood pressure, lipid profile and inflammation parameters in patients with type 2 diabetes mellitus.
|
Diabetol Metab Syndr
|
2016
|
0.77
|
|
67
|
Effect of Intensive Blood Pressure Lowering on Incident Atrial Fibrillation and P-Wave Indices in the ACCORD Blood Pressure Trial.
|
Am J Hypertens
|
2015
|
0.77
|
|
68
|
Microvascular Outcomes in Patients with Type 2 Diabetes Treated with Vildagliptin vs. Sulfonylurea: A Retrospective Study Using German Electronic Medical Records.
|
Diabetes Ther
|
2016
|
0.75
|
|
69
|
Evaluation of an automated method to assist with error detection in the ACCORD central laboratory.
|
Clin Trials
|
2010
|
0.75
|
|
70
|
Biomarkers associated with severe hypoglycaemia and death in ACCORD.
|
Diabet Med
|
2015
|
0.75
|